News

PharmExec13h
AstraZeneca, CSPC Launch AI-Powered Collaboration for Oral Drug Discovery
Under terms of the deal, CSPC will receive $110 million upfront, with potential milestone payments reaching up to $5.22 ...
AstraZeneca slips Monday, underperforms market
AstraZeneca PLC closed 19.20% below its 52-week high of £133.88, which the company achieved on September 3rd.
Business Weekly13h
AstraZeneca takes spending on novel China projects to around $8bn
Cambridge headquartered global pharmaceutical company AstraZeneca took its spending on China plays in the last month to ...
AstraZeneca: Fascinating Company With Lofty Ambitions - Just Not A Buy Yet
AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.
KSL10d
AstraZeneca sues Utah attorney general over new Utah drug price law
The pharmaceutical drug company AstraZeneca filed a lawsuit against the Utah attorney general claiming Utah's new law on ...
AstraZeneca sues Utah attorney general over new drug pricing law
AstraZeneca, a major pharmaceutical company, has sued Utah’s Attorney General Derek Brown over a recently passed state law ...
Explore more
sharewise55m
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
Astrazeneca (AZN) closed the most recent trading day at $73.55, moving -1.17% from the previous trading session. The stock's ...
Fierce Pharma15h
AstraZeneca touts early Ultomiris survival data in children living with rare post-transplant complication
Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug ...